Chilean study reveals success of various COVID-19 vaccines

pharmafile | August 4, 2021 | News story | Research and Development  

Chilean authorities have released real world data on the varied success of the Sinovac, Pfizer, and AstraZeneca COVID-19 vaccines.

Among the millions of Chileans who have been vaccinated between February and July, the Sinovac jab was 58.5% effective in preventing symptomatic illness, while Pfizer’s was 87.7% effective and AstraZeneca’s was 68.7% effective.

Chile’s vaccination rollout has been one of the fastest globally, having now fully vaccinated more than 60% of its population, predominantly with Sinovac’s CoronaVac.

That vaccine was 86% effective in preventing hospitalisation, 89.7% effective in preventing admission to intensive care units and 86% effective in preventing deaths within the population between February and July, health official Dr Rafael Araos said in a press conference on Tuesday.

In April, the same study found that CoronaVac was 67% effective in preventing symptomatic illness, 85% effective in preventing hospitalisations and 80% effective in preventing deaths, suggesting its capacity to prevent the more serious impacts of the virus has strengthened, while its capacity to stop symptomatic illness diminished.

Araos said a reduction in protection from vaccines was inevitable over time, particularly with the arrival and growing prevalence of more virulent strains such as the Delta variant.

“If Delta becomes more prevalent and the vaccine has a weaker response, we could observe a faster fall (in effectiveness),” he said, adding his voice to calls for a third, booster dose to be issued.

Kat Jenkins

Related Content

No items found

Latest content